Major R&D Facilities
Bristol-Myers Squibb's drug discovery and development work takes place across a network of state-of the-art facilities worldwide.
The Biocon Bristol-Myers Squibb Research & Development Center (BBRC) is a collaboration between Bristol-Myers Squibb and Syngene International, a Biocon- group company, and is based in Bangalore, India. This state-of-the-art 200,000 sq ft facility houses integrated R&D capabilities for over 450 scientists. Fully operational since 2009, the site is involved in Target Identification, Lead Discovery and Lead Optimization all the way through to early stage Pharmaceutical Development and Clinical Biomarkers R&D.
Bristol-Myers Squibb's European R&D operations have been based here since 2003. Currently there are nearly 400 employees at this site, 250 of them in R&D who focus on Global Regulatory Sciences and various R&D clinical operations activities. Employees work in eight buildings located in an office park set in the countryside.
Hopewell, New Jersey
Acquired in 1997, some of the company's most important drug discovery work takes place at this 433-acre site, particularly in cardiovascular and metabolic diseases. Surrounded by forest and farmland, the campus has approximately 2,200 employees with about 1,000 in R&D. Eight major buildings reside on the site, totaling 800,000 square feet.
The 11.2 acre research facility is located on the Wirral Peninsula between Chester and Liverpool. Scientists here investigate new medicinal compounds and how they can be manufactured efficiently on a commercial scale.
New Brunswick, New Jersey
Purchased in 1905 when E.R. Squibb & Sons relocated operations from Brooklyn, New York, this campus has 40 buildings that total 1.9 million square feet on 96 acres and is occupied by more than 1,500 employees. The site has evolved from a manufacturing site to become Bristol-Myers Squibb's center for excellence for our therapeutic compounds.
Plainsboro, New Jersey
This 106-acre facility opened in 1992 and is the headquarters of Bristol-Myers Squibb's U.S. Operations and R&D U.S. Medical Affairs Group. The campus has more than 1,300 employees, of which approximately 400 are in R&D focused on Global Development and Medical Affairs. Three five-story office buildings total 680,000 square feet.
Princeton, New Jersey
The 276-acre campus serves as Bristol-Myers Squibb's R&D headquarters, with more than 1,900 employees, 1,340 of them in R&D. Here scientists discover and develop medicines in the areas of cancer, immunology, and cardiovascular and metabolic diseases. The campus has 13 connected buildings totaling 1.5 million square feet.
Bristol-Myers Squibb's European and French headquarters located 45 minutes from downtown Paris. The building, opened in August 2002, was designed by internationally recognized architect Jean-Paul Viguier and houses approximately 850 employees, about 40 in R&D focused on Global Development and Medical Affairs.
San Francisco Bay Area, California
The 132,000 square foot Bay Area research facility houses biologics drug discovery activities focused on antibody therapeutics.
The Redwood City location provides proximity to major biomedical research centers such as UC Berkeley, UC San Francisco and Stanford University.
A renewed Seattle landmark steam plant now provides a high-tech home for ZymoGenetics, a biotechnology firm acquired by Bristol-Myers Squibb in 2010. With approximately 190 employees, ZymoGenetics discovers and develops therapeutic proteins for the prevention and treatment of serious diseases.
Since 1995, Bristol-Myers Squibb has occupied 76,000 square feet of an office building in Nishi-Shinjuku, Tokyo. Four hundred of our approximately 1,000 employees in Japan work at this site, including about 250 in R&D in Medical Affairs, Pharmacovigilance, Regulatory, Clinical Strategies, Clinical Operations, Data Management and Early Development.
This research facility was originally established in 1986 as Bristol-Myers' research and development headquarters. It now has 1,200 employees, the majority of them in R&D dedicated to discovering and developing medicines, particularly in the areas of neuroscience, virology and cancer.
The Waltham facility is a discovery site with approximately 100 employees. It is part of the larger business unit, Molecular Discovery Technologies, which supports the identification and optimization of drug candidates across modalities in Discovery R&D.